Press releaseGlobe Newswire
AxoGen
AXGN · NASDAQ
$36.17+$0.93 (+2.64%)TodayMarket closed ·
Prev close $35.24
Latest news
- Press releasePRNewswire
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
- News
10 Health Care Stocks Whale Activity In Today’s Session
- NewsVandana Singh
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
- News
Axogen To Acquire NerveTape Maker BioCircuit Technologies For $200M In Cash; Sees Deal As Accretive To FY27 Gross And Adjusted EBITDA Margins
- Press releaseGlobe Newswire
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
- Press releaseGlobe Newswire
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
- Press releasePRNewswire
Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
- News
Axogen Q2 Adj. EPS $0.12 Misses $0.13 Estimate, Sales $69.731M Beat $67.098M Estimate
- Press releaseGlobe Newswire
Axogen, Inc. Reports Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
- Press releaseGlobe Newswire
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
- News
Full Transcript: Axogen Q1 2026 Earnings Call
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Axogen, Inc. Reports First Quarter 2026 Financial Results
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
- News
Axogen Earnings Preview
- News
Beyond The Numbers: 6 Analysts Discuss Axogen Stock
- NewsVandana Singh
Axogen Prices Upsized $124 Million Stock Offering
- Press releaseGlobe Newswire
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
- NewsVandana Singh
Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment
- Press releaseGlobe Newswire
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
- Press releaseBusiness Wire
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN
- Press releaseBusiness Wire
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.